4SC AG ended the 2011 first quarter with an operating loss of €4.8 million and cash and equivalents of €5.5 million. The German small-molecule developer said it is expecting final Phase 2 data this year from three important studies. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
